We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Trellus Health Plc | LSE:TRLS | London | Ordinary Share | GB00BNNFM402 | ORD GBP0.0006 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.25 | -11.11% | 2.00 | 559,688 | 16:40:53 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.80 | 2.00 | 2.25 | 1.90 | 2.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices Of Medical Doctors | USD 18k | USD -8.81M | USD -0.0545 | -0.35 | 3.07M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:40:53 | UT | 4,667 | 2.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/4/2024 | 13:31 | ALNC |  EARNINGS: Videndum warns on recovery; AB Dynamics expects profit beat |
| 23/4/2024 | 07:00 | UK RNS | Trellus Health PLC Preliminary Results |
| 17/4/2024 | 16:16 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 16/4/2024 | 17:02 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 16/4/2024 | 07:00 | UK RNS | Trellus Health PLC Notice of Results |
| 02/4/2024 | 16:36 | UK RNS | Trellus Health PLC Holding(s) in Company |
| 05/3/2024 | 07:00 | UK RNS | Trellus Health PLC Grant of Share Options |
| 28/2/2024 | 12:00 | UK RNS | Trellus Health PLC Directorate Change |
| 28/2/2024 | 10:42 | ALNC | Trellus Health inks deal with "large US health plan" |
| 28/2/2024 | 07:00 | UK RNS | Trellus Health PLC Agreement with US Health Plan |
Trellus Health (TRLS) Share Charts1 Year Trellus Health Chart |
|
1 Month Trellus Health Chart |
Intraday Trellus Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/4/2024 | 18:11 | Trellus Health - Digital Health Solution for complex chronic conditions | 315 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:40:53 | 2.00 | 4,667 | 93.34 | UT |
| 14:42:00 | 2.00 | 39,752 | 795.04 | O |
| 13:25:52 | 2.00 | 50,000 | 1,000.00 | O |
| 13:13:46 | 2.00 | 56,726 | 1,134.52 | O |
| 13:13:22 | 2.00 | 60 | 1.20 | O |
| Top Posts |
|---|
Posted at 24/4/2024 09:20 by Trellus Health Daily Update Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 2.25p.Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £3,068,658. Trellus Health has a price to earnings ratio (PE ratio) of -0.35. This morning TRLS shares opened at 2.25p |
Posted at 23/4/2024 11:55 by idomeneo Total of 180 downloads (all time):More data about Trellus Health Price Free to download Total downloads 180 Recent downloads 16 Rating No ratings Ranking Not ranked Version 1.96.0 APK size 43.8 MB Number of libraries ? Suitable for Everyone Ads NO ads |
Posted at 19/12/2023 13:46 by hatfullofsky Very strange price action here |
Posted at 01/12/2023 12:24 by hatfullofsky TRLS are now trading 40% below their cash level |
Posted at 03/10/2023 16:10 by hatfullofsky I was waiting for the user numbers too and to hear they have moved the 130 [paying] members $100 / month to a free service as part of a community feedback programme really hurt. There is clearly no demand in the D2C model and that's why they pushed the B2B emphasis on the investor call.If this tool does save money for the payer there is a clear business case. You could see the health care provider making it mandatory for all IBS / IBD sufferers. But the "potential share of savings" being the "significant upside" worries me when they have no users yet 6,200 members at $1,250 is breakeven £7.75m so current cash levels support the 2025 timeline. Their current pilot programmes have a TAM of 325 users and we'll only get results in Q2-24. They alluded to signing a major pilot programme (I guess before year end), that will attract interest and then the results in Q2 but really we are going to be waiting a long time for this to ignite |
Posted at 01/9/2023 13:06 by hatfullofsky Breakeven is on the IMC slide deckAt $100 per patient per month, breakeven at 6200 members (2.5% of TAM)Cash at $19m 2022 v $24m 2021, burn below $700k per month in 2023, cash into 2025 (at current revenue levels and capital investment)In early and late stage discussions with several health plans 2023 expecting revenue take off as 2022 pilot contracts roll into commercial agreements.130 patients currently enrolled (a long way to 6200)TRLS need to announce contracts and enrolment numbers for this to recover |
Posted at 25/4/2023 18:23 by idomeneo This might not be the bottom but I bought £5k here. There are lots of negatives, but there is time and cash (it qualifies as a Ben Graham Net Net which has returned 460% over the last 11 years). They may need a stock market oriented CEO who is prepared to do the things which creates the noise to get people interested, but in the meantime we have a results day plus hopefully an "Investor Meet Company" or similar following that. There was no liquidity for that £5k, so it is just available to private punters at this price. No guarantee at all of a long term win, but that doesn't have to matter. Could tank to 4p if they come with nothing to say. |
Posted at 11/4/2023 09:31 by mikemine1 TRLS seems to fit right in there with the Commission's view of the future. Well done Wan. |
Posted at 28/2/2023 10:11 by wan Well, do we assume that the delay of around 6 weeks in launching the D2C IBS offering (still ahead of the originally expected launch for IBS in H1 2023) has had a bearing on the delayed TU?Not to mention the progression to late-stage discussions with several pharma co.'s and patient services partners who deliver programs to pharmaceutical companies, is perhaps also taking longer, and I can see that some pharma's have an interest in addressing IBS (and IBD e.g. Takeda), and that a certain patient service partner covers IBS, but not IBD. I am trying to remain somewhat optimistic (but it's wearing thinner by the day) but in any regard, the share price performance since admission to AIM has been utterly uninspiring, and thus the management have a 'lot' to do to change that! |
Posted at 24/2/2023 14:47 by wan Idomeneo...I agree that the CEO is excellent.Certainly the share price performance appears to be reflecting disappointment, and not reporting as guided is clearly not helping matters. And lets face it, whilst the recent updates have been encouraging, none of them have been game changing, but they should nonetheless contribute positively this year. The increasing interest from pharmaceutical companies and the progression to late-stage discussions (with at least two), might change the dynamics if they can successfully conclude something material. Perhaps those discussions are taking longer, and they had hoped to include them as part of the detailed trading update, which in turn would imply they might be close to concluding? I also have my eye on larger entities in the healthcare space where partnering with Trellus in addressing chronic conditions (initially IBD & IBS), could make a good fit strategically (expanding to address other chronic conditions, and/or some already covered by those entities), especially given that Trellus Health is the first and only digital health company to offer a 'scientifically validated', personalised resilience-based self-management training program for people living with chronic conditions which has been proven to reduce unplanned hospitalizations by 94%. After the disappointingly slow progress to date though, and the market in a state of being very unforgiving, updates of only incremental progress will hardly be well received given the early stage Trellus is at. |
Posted at 14/12/2021 10:43 by cambridgedon Thanks Wan.Seems that the RENX and TRls share prices are suffering at the same time! In one sense they both represent a lot lower risk than at the IPO/launch price but the recent falls have also got many to question what they are really worth. Thoughts? CD |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
